Purpose. The pharmacology, antimicrobial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of ceftobiprole are reviewed. Conclusion. Ceftobiprole is a ...

The Annals of Pharmacotherapy. 2008;42(6):806-816. Patients were randomized to receive either ceftobiprole 500mg intravenously over 60 minutes every 12 hours or vancomycin 1 g intravenously over ...

Basilea will seek approval of ceftobiprole for SAB as well as acute bacterial skin and skin structure infection (ABSSSI) based on the results of the earlier TARGET study which showed non ...

Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 16, 2024Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a ...